Amylyx is a commercial stage company developing proprietary therapeutics for Amyotrophic Lateral Sclerosis and other neurodegenerative diseases. ALS IF exited the company in 2023.

Apic Bio Inc. (”Apic”) is a Boston based gene therapy company with a clinical stage program and a new, ground breaking technology platform. KIID (EID) DUTCH, KIID (EID) ENG

Bloom Science is a clinical-stage biotech company advancing a deep pipeline of programs that target the Gut-Brain axis for indications including Dravet syndrome, other rare epilepsies, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders. KIID (EID) DUTCH, KIID (EID) ENG

The platform offers researchers a new standard for predicting how a human may respond to medicines, chemicals, and foods — with greater precision and control than today’s cell culture or animal-based testing methods. KIID (EID) DUTCH, KIID (EID) ENG

Orphazyme was founded in 2009 with the objective to develop new therapies for patients suffering from protein-misfolding diseases with no or limited treatment options available. ALS IF exited the company in 2022.

Prilenia is a clinical stage biotech company, founded by the former President of Global R&D and CSO of Teva, with 2 late stage programs for ALS and Huntington's disease currently in development. KIID (EID) DUTCH, KIID (EID) ENG

ProJenX was founded in 2021, a spin-out from Columbia University and Project ALS, based on robust scientific evidence of MAP4 kinases being critical regulators of motor neuron loss in ALS. The company is currently conducting a Ph1 clinical study.

QurAlis is a clinical stage biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases. KIID (EID) DUTCH, KIID (EID) ENG

Verge is a clinical stage biotech company that was founded on the belief that exponential advances in computational genomics, combined with new insights in neuroscience, will lead to breakthrough opportunities to identify targets and discover drugs that can dramatically improve the lives of patients suffering from neurodegenerative diseases. KIID (EID) DUTCH, KIID (EID) ENG

VectorY is an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives. KIID (EID) DUTCH, KIID (EID) ENG